UK HealthCare logo

Practice areas

  • Gastroenterology and Hepatology

Faculty rank

Assistant Professor of Medicine

Clinic information

Clinical interests

  • Hepatology
  • Liver Transplantation
  • Viral Hepatitis



Medizinische Hochschule Hannover, Hannover, Germany


Medizinische Hochschule Hannover, Hannover, Germany


Medizinische Hochschule Hannover, Hannover, Germany

Additional information


My name is Jens Rosenau; I specialize in general hepatology, with a focus on viral hepatitis, hepatocellular carcinoma, and the management of pre- and post-liver transplant patients.

After receiving my medical degree from Hanover Medical School in Germany, I continued to work there in the Division of Gastroenterology and Hepatology for almost 10 years, contributing to the one of the highest output hepatology research divisions in Germany and one of the largest transplant programs in Europe.

I have authored several clinical research articles. I am on editorial boards of international medical journals and an active as a peer reviewer.


  1. Crittenden NE, Buchanan LA, Pinkston CM, Cave B, Barve A, Marsano L, McClain CJ, Jones CM, Marvin MR, Davis EG, Kuns-Adkins CB, Gedaly R, Brock G, Shah MB, Rosenau J, Cave MC. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation. Liver Transpl. 2016 May;22(5):635-43.
  2. Rajagopalan N, Hoopes CW, Rosenau J. Hepatitis C virus infection in heart transplantation: is ventricular assist device therapy an option? Transplantation. 2013 Aug 27;96(4):e23-4. doi: 10.1097/TP.0b013e31829c24a6. No abstract available.
  3. Rifai K, Pischke S, Agne C, Rosenau J, Klempnauer JL, Manns MP. High rate of unperceived hearing loss in patients after liver transplantation. Clin Transplant. 2012 Jul-Aug;26(4):577-80. doi: 10.1111/j.1399-0012.2011.01592.x. Epub 2012 Jan 26.
  4. Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, Zacher BJ, Heidrich B, Tillmann HL, Rosenau J, Bock CT, Savas B, Helfritz F, Lehner F, Strassburg CP, Klempnauer J, Wursthorn K, Lehmann U, Manns MP, Herrmann E, Wedemeyer H. Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. J Hepatol. 2012 Jan;56(1):115-22. doi: 10.1016/j.jhep.2011.06.016. Epub 2011 Jul 14.
  5. Rifai K, Das A, Rosenau J, Ernst T, Kretschmer U, Haller H, Fliser D, Manns MP. Changes in plasma amino acids during extracorporeal liver support by fractionated plasma separation and adsorption. Artif Organs. 2010 Feb;34(2):166-70. doi: 10.1111/j.1525-1594.2009.00763.x. Epub 2009 Oct 10.
  6. Wiegand J, Wedemeyer H, Finger A, Heidrich B, Rosenau J, Michel G, Bock CT, Manns MP, Tillmann HL. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther. 2008;13(4):547-54.
  7. Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, Klempnauer J, Tillmann HL, Manns MP, Rosenau J. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl. 2008 Apr;14(4):435-42. doi: 10.1002/lt.21343.
  8. Rifai K, Wedemeyer H, Rosenau J, Klempnauer J, Strassburg CP, Manns MP, Tillmann HL. Longer survival of liver transplant recipients with hepatitis virus coinfections. Clin Transplant. 2007 Mar-Apr;21(2):258-64.
  9. Rosenau J, Hooman N, Hadem J, Rifai K, Bahr MJ, Philipp G, Tillmann HL, Klempnauer J, Strassburg CP, Manns MP. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl. 2007 Mar;13(3):367-73.
  10. Rosenau J, Kreutz T, Kujawa M, Bahr MJ, Rifai K, Hooman N, Finger A, Michel G, Nashan B, Kuse ER, Klempnauer J, Tillmann HL, Manns MP. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol. 2007 Apr;46(4):635-44. Epub 2007 Jan 25.
  11. Rifai K, Hafer C, Rosenau J, Athmann C, Haller H, Peter Manns M, Fliser D. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). Scand J Gastroenterol. 2006 Oct;41(10):1212-7.
  12. Rosenau J, Hooman N, Rifai K, Solga T, Tillmann HL, Grzegowski E, Nashan B, Klempnauer J, Strassburg CP, Wedemeyer H, Manns MP. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int. 2006 Oct;19(10):828-33.
  13. Rifai K, Kirchner GI, Bahr MJ, Cantz T, Rosenau J, Nashan B, Klempnauer JL, Manns MP, Strassburg CP. A new side effect of immunosuppression: high incidence of hearing impairment after liver transplantation. Liver Transpl. 2006 Mar;12(3):411-5.
  14. Tillmann HL, Bock CT, Bleck JS, Rosenau J, Böker KH, Barg-Hock H, Becker T, Trautwein C, Klempnauer J, Flemming P, Manns MP. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl. 2003 Feb;9(2):191-6.
  15. Bahr MJ, Rosenau J, Manns MP. Discussion on the association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002 Dec;123(6):2160; author reply 2160. No abstract available.
  16. Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, Lang H, Klempnauer J, Manns MP, Boeker KH. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation. 2002 Feb 15;73(3):386-94.